Trial Profile
A Single Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 1064 (Primary)
- Indications Insomnia
- Focus Adverse reactions; Pharmacokinetics
- Acronyms MK-1064-001
- Sponsors Merck Sharp & Dohme
- 16 Sep 2015 New trial record